78 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
as part of an IND along with other information, including information about product CMC and a proposed clinical trial protocol. Long term preclinical … strategic goals and create long-term value for our shareholders. We provide employees with what we consider to be a very competitive mix of compensation
F-3
EX-4.1
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
compensation comprises the base salary and other compensation elements. Variable compensation may comprise short-term and long-term compensation elements … financiers, ainsi que des éléments de rétention.
Long-term variable compensation elements shall be governed by performance metrics that take into account
6-K
EX-99.3
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
, fixtures and equipment
Intangible assets
Other long-term assets
Total non-current assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current … liabilities
Non-current lease liabilities
Non-current borrowings
Post-employment obligations
Other long-term liabilities
Total non-current liabilities
6-K
EX-99.1
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
Right-of-use assets
Furniture, fixtures and equipment
Intangible assets
Other long-term assets
Total non-current assets
Total assets
LIABILITIES … current liabilities
Non-current liabilities
Non-current lease liabilities
Non-current borrowings
Post-employment obligations
Other long-term liabilities
6-K/A
EX-99.1
OBSVF
ObsEva SA
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
Total current assets
Non-current
assets
Right-of-use
assets
Furniture, fixtures and equipment
Intangible assets
Other long-term assets
Totalnon-current … long-term liabilities
Totalnon-current
liabilities
Shareholders’ equity
Share capital
Share premium
Reserves
Accumulated losses
Total shareholders
6-K
EX-99.1
6vi9i95
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.1
ervq8yimoam
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
aiwmr3
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.1
i1q9om hmsta
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.3
xoejggsfx02
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
vjsn 1vg3agt
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
f9xnx3xpe96h 6ljn
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
F-3
EX-4.1
fq2ug
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
kcgr4ly
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
himngw60zqni 0iwow0i
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
h8p2b51
13 Dec 21
ObsEva Appoints Will Brown as Chief Financial Officer
7:00am
6-K
EX-99.1
cspu6
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.1
oi6a6z98yk tvj
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am